ATE373721T1 - Verpackung von replikon-partikeln eines positiv- strängigen rna-virus - Google Patents

Verpackung von replikon-partikeln eines positiv- strängigen rna-virus

Info

Publication number
ATE373721T1
ATE373721T1 AT01973668T AT01973668T ATE373721T1 AT E373721 T1 ATE373721 T1 AT E373721T1 AT 01973668 T AT01973668 T AT 01973668T AT 01973668 T AT01973668 T AT 01973668T AT E373721 T1 ATE373721 T1 AT E373721T1
Authority
AT
Austria
Prior art keywords
replicon particles
packaging
rna virus
strand rna
packaging systems
Prior art date
Application number
AT01973668T
Other languages
English (en)
Inventor
Gerald Kovacs
Nikolaos Vasilakis
Jacek Kowalski
Timothy J Zamb
Seema S Gangolli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE373721T1 publication Critical patent/ATE373721T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
AT01973668T 2000-08-29 2001-08-28 Verpackung von replikon-partikeln eines positiv- strängigen rna-virus ATE373721T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22890600P 2000-08-29 2000-08-29

Publications (1)

Publication Number Publication Date
ATE373721T1 true ATE373721T1 (de) 2007-10-15

Family

ID=22859031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973668T ATE373721T1 (de) 2000-08-29 2001-08-28 Verpackung von replikon-partikeln eines positiv- strängigen rna-virus

Country Status (13)

Country Link
US (2) US7034141B2 (de)
EP (1) EP1326990B1 (de)
JP (1) JP2004507249A (de)
KR (1) KR20030074594A (de)
CN (1) CN1250731C (de)
AT (1) ATE373721T1 (de)
AU (2) AU9322201A (de)
BR (1) BR0113577A (de)
CA (1) CA2424052A1 (de)
DE (1) DE60130569D1 (de)
IL (1) IL154169A0 (de)
MX (1) MXPA03001680A (de)
WO (1) WO2002018585A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP1326990B1 (de) * 2000-08-29 2007-09-19 Wyeth Holdings Corporation Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
WO2002072803A2 (en) * 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
UA82479C2 (uk) * 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
US20040053225A1 (en) * 2002-09-13 2004-03-18 Large Scale Biology Corporation Enhancement of virus induced gene silencing (VIGS) through viral-based expression of inverted-repeats
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
EP1608762B1 (de) * 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
WO2004087201A2 (en) * 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
EP1678292A4 (de) * 2003-09-18 2008-05-07 Univ Emory Verbesserte mva-impfstoffe
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
EP1835031A1 (de) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verwendung eines rekombinanten modifizierten Vaccinia Ankara Virus (MVA) zur Behandlung der Typ-I Hypersensitivität in einem lebenden Tier einschließlich des Menschen
EP1925318A1 (de) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Rekombinanter modifizierter Vaccinia Virus Ankara (MVA)-basierter Impfstoff gegen Vogelgrippe
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
CN101226196B (zh) * 2008-02-02 2012-05-09 南方医科大学 一种检测ⅱ型登革病毒ns1抗原的免疫诊断试剂盒
WO2010039649A2 (en) * 2008-10-03 2010-04-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus-based system for production of hepatitis c virus (hcv)
CN101551393B (zh) * 2009-04-02 2012-09-19 南方医科大学 一种检测ⅳ型登革病毒ns1抗原的免疫诊断试剂盒
CN104513820B (zh) * 2013-09-30 2017-08-04 中国人民解放军军事医学科学院微生物流行病研究所 DNA片段及其在制备H5N1亚型流感Guassia荧光素酶报告病毒中的应用
EP3105311A1 (de) 2014-02-10 2016-12-21 Univercells NV System, vorrichtung und verfahren zur herstellung von biomolekülen
US20190002838A1 (en) 2015-06-19 2019-01-03 Seracare Life Sciences, Inc. Sindbis control virus
WO2017129765A1 (en) 2016-01-29 2017-08-03 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2018023473A1 (zh) * 2016-08-03 2018-02-08 台湾生物制剂股份有限公司 以整体表现细胞作为抗原载体及其于制备疫苗或诊断试剂及筛选单株抗体的应用
US11229699B2 (en) 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
WO2019115090A1 (en) * 2017-12-15 2019-06-20 Intervet International B.V. Multivalent feline vaccine
CN109806390A (zh) * 2019-01-07 2019-05-28 康希诺生物股份公司 一种SamRNA疫苗及其制备方法
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用
EP3782465B1 (de) 2019-08-23 2023-08-30 Universität Potsdam Transgenes zebrafischmodell für schlaganfall
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
EP1326990B1 (de) * 2000-08-29 2007-09-19 Wyeth Holdings Corporation Verpackung von replikon-partikeln eines positiv-strängigen rna-virus

Also Published As

Publication number Publication date
AU9322201A (en) 2002-03-13
US20060141602A1 (en) 2006-06-29
KR20030074594A (ko) 2003-09-19
CA2424052A1 (en) 2002-03-07
US7034141B2 (en) 2006-04-25
BR0113577A (pt) 2004-07-06
US20040029279A1 (en) 2004-02-12
EP1326990A2 (de) 2003-07-16
CN1471583A (zh) 2004-01-28
IL154169A0 (en) 2003-07-31
WO2002018585A2 (en) 2002-03-07
WO2002018585A8 (en) 2003-04-24
JP2004507249A (ja) 2004-03-11
MXPA03001680A (es) 2004-11-01
WO2002018585A3 (en) 2003-01-23
EP1326990B1 (de) 2007-09-19
CN1250731C (zh) 2006-04-12
DE60130569D1 (de) 2007-10-31
AU2001293222B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
DE60130569D1 (de) Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
ATE426412T1 (de) Adjuvante influenza-vakzine
BRPI0111830B8 (pt) método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
IL145702A0 (en) Recombination influenza viruses for vaccines and gene theraphy
GR3032416T3 (en) Chimeric and/or growth-restricted flaviviruses.
ZA936629B (en) Potentiation of immunogenic response
PT1032374E (pt) Esferoides processo de preparacao e composioes farmaceuticas
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
AU6365301A (en) Vaccine
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO2004039945A3 (en) Preventive and therapeutic aids vaccines
MXPA04000431A (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno.
MY145463A (en) Flavivirus ns1 subunit vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties